RESILIENT logo

RESILIENT

RandomisEd, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with Exenatide QW versus dapagliflozin alone in obese (BMI>30 kg/m2) patients with Type 2 diabetes mellitus.

RESILIENT

RandomisEd, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with Exenatide QW versus dapagliflozin alone in obese (BMI>30 kg/m2) patients with Type 2 diabetes mellitus.
Funding AstraZeneca
Portfolio Clinical Specialties
Interventions Medicine
Randomised Yes
Status Recruiting
Start Date 06-Oct-2017

The purpose of this study is to determine the benefits of using dapagliflozin (an SGLT2 inhibitor) and exenatide QW (once a week GLP-1 receptor agonist) in combination.

Obesity is a major risk factor for diabetes. Some treatments for diabetes can cause patients to put on weight but newer treatments for diabetes target weight loss in addition to improving blood glucose control. There have been two new promising medications available for treating Type 2 diabetes: the GLP-1 receptor agonist and the SGLT2 inhibitor. Both are associated with significant improvement in blood glucose levels and in body weight. To date there is no evidence about using these two drugs together even though we think there are good reasons to do this. We think that if we use these medications together they will complement each other improving weight loss and blood glucose control.

Publications

  • N/A